PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Subdivisions of Program Areas, these track general higher level sub-classifications of expenditure.
Subdivisions of Major categories, these are the most detailed expenditure data.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2008
This is a continuing activity from FY06 and FY07.
Dispensing, Rational Use and Site-level Inventory Management of Antiretroviral (ARV) Drugs and Related
This activity focuses on facility-level stock management of essential HIV commodities, such as ARV and
opportunistic infection (OI) drugs, lab supplies, prevention of drug expiry by shifting stock among facilities,
and raising the current low standard of dispensing to acceptable levels. The activity is related to good
clinical and pharmacy practice and is a component of the rational use of drugs (rational prescribing, rational
dispensing, and rational use by the patient). Management Sciences for Health/Rational Pharmaceutical
Management Plus (MSH/RPM+) will continue to collaborate with the Drug Administration and Control
Authority (DACA), the Provisional Supplies and Logistics Department (PSLD) of the Ethiopian Ministry of
Health (MOH), the Partnership for Supply Chain Management (PSCMS), as well as new entities such as the
US President's Malaria Initiative(PMI), and the MSH Care and Support Program, and other relevant
organizations, to implement rational HIV commodity dispensing and use for ARV, OI drugs, malaria and
tuberculosis (TB) products, PMTCT supplies, laboratory reagents and test kits at ART facilities It will
support facilities in submitting monthly orders using facility-based data; in collaboration with DACA, Abt
Associates, and as part of the public-private partnership (PPP) effort, it will provide technical assistance
(TA) to Kenema (City Council), Red Cross, and selected private pharmacies in storing and dispensing ARV
and related commodities.
Improving Quality Assurance of ARV and Related Commodities
Quality assurance of ARV and other drugs plays a vital role in guaranteeing favorable treatment outcomes
and decreasing toxicity. This is a continuing activity from FY06 and FY07. MSH/RPM+ will continue to
provide TA to DACA by seconding Quality Control/Quality Assurance (QC/QA) pharmacists and supporting
regional activities to ensure the quality, safety, and efficacy of HIV/AIDS, TB, malaria, and OI drugs.
DACA's capacity to monitor and control the movement of counterfeit pharmaceuticals will be strengthened.
DACA's drug QC laboratory will be supported in the proper storage of reagents and chemicals, record-
keeping, and provision of reference books and standards, computers and accessories, TA in the
development of new standard operating procedures (SOP) and in managing an electronic database and
reporting system for their QC Laboratory. In collaboration with PSMCS, MSH/RPM+ will support DACA and
PHARMID's efforts in post-marketing surveillance of drugs, establishing six QC mini-labs at selected sites.
Strengthening Site-Level Pharmaceutical and Laboratory Information Management
This activity will assure that there are no treatment interruptions due to stock-outs of vital products, will
minimize expiry of expensive drugs. RPM+ has implemented pharmacy-based patient medication records
for more than 70,000 ART patients nationwide; some are computerized. Facilities have been provided with
over 50 computers and printers and 62 pharmacy data clerks have been deployed to hospitals and health
centers to ensure quality data entry and reporting. These activities will be maintained and further expanded
In FY08. RPM+ will support health facilities in preparing scheduled orders of HIV commodities, and will
support PSCMS in distributing these items from PHARMID regional stores to facilities. MSH/RPM+ will build
on the experience to date, scaling up inventory management, patient pharmacy records, and reporting at
facility level and ensuring that ART SOP and pharmacy-related formats and registers are available at all
ART/PMTCT sites. Routine commodity audit systems will be introduced at all ART sites. Target facilities will
be provided with computers and printers. Access to telephones and the Internet will continue to be
supported to facilitate reporting and track defaulters. In order to ensure ownership and use of data, data
managers will be recruited and deployed at regional health bureaus (RHB).
Facility-level data will be compiled, analyzed, and shared with relevant agencies for quantification and
redistribution. Monitoring of ARV drug management and use will be supported. In consultation with PSCMS
and other partners, MSH/RPM+ will continue to work on implementing an electronic tool to manage
information on laboratory commodities.
Strengthening Pharmacy Human Resource Capacity
This activity is part of an overall human resource (HR) capacity-building effort with local and US universities,
the Clinton HIV/AIDS Initiative (CHAI), and JHPIEGO. HR-related constraints are perhaps the greatest
challenge for the health system at present. In conjunction with the Ethiopian Pharmaceutical Association,
pre-service and in-service training will be provided to pharmacy personnel and students. To date RPM+ has
trained more than 1,400 pharmacy and allied professionals in HIV-product management and rational drug
use (RDU). Refresher trainings need to be conducted to update staff and address high staff turnover. ART
site staff will be trained in supply management, pharmaceutical care, and RDU, as well as basic computer
skills. Training will be followed by supportive supervision and mentoring. External short-term training in
relevant areas will be facilitated for selected participants. In collaboration with DACA, RPM+ will promote
public awareness and education by training media personnel to promote RDU, including containment of
antimicrobial resistance (AMR), adherence, awareness about counterfeits, etc., and providing up-to-date
specialty books and reference materials to health facilities. A critical task assigned to MSH/RPM+ by the
MOH during the plan year is the assessment of pharmaceutical HR needs and development requirements
of the pharmaceutical sector as outlined in the Pharmaceutical Sector Master Plan.
Provision of Technical Assistance and Coordination
RDU is a key element to maximize treatment options for chronic diseases such as HIV/AIDS. Monitoring
and minimizing adverse drug reactions (ADR) is instrumental in increasing adherence to treatment, which
supports the success of treatment. Clients will get improved pharmaceutical care, and the development of
viral or AMR will be minimized. TA will be provided in the following areas: 1) RDU; (2) establishing drug and
therapeutic committees (DTC) and drug information centers (DIC), in collaboration with DACA, PSLD, RHB,
CHAI's Hospital Improvement Initiative and others; (3) AMR containment; (4) ADR monitoring; and 5)
adherence monitoring and promotion through workshops, studies, and development of facility-level action
plans. Activities envisaged include collaboration with programs such as the new Care and Support Program
at health centers, at community and household levels with health extension workers, through HIV/TB drug
management, with PMI in management and rational use of malaria products; and by linkages with
stakeholders to conduct drug-related operational research. Working closely with DACA and PSLD, RPM+
will support improved governance in the pharmaceutical sector by providing TA in pharmaceutical policy,
regulation, and quality services in support of the national pharmaceutical and logistics master plans, and will
collaborate with the MOH, DACA, PSCMS, and the Implementation Support Team (IST) of the Logistics
Master Plan in the transformation of PSLD to the "New PSLD" and PHARMID to the new Agency.
Activity Narrative: This is a continuing activity from FY06 and FY07.